Benefits of frequent nocturnal home hemodialysis  by Misra, Madhukar & Twardowski, Zbylut J.
3. Kabir A, Nadasdy T, Nadasdy G et al. An unusual cause of gross hematuria
and transient ARF in an SLE patient with warfarin coagulopathy. Am J
Kidney Dis 2004; 43: 757–760.
4. Brodsky SV, Satoskar A, Chen J et al. Acute kidney injury during warfarin
therapy associated with obstructive tubular red blood cell casts: a report of
9 cases. Am J Kidney Dis. 2009; 54: 1121–1126.
5. Brodsky SV, Nadasdy T, Rovin BH et al. Warfarin related nephropathy
occurs commonly in both those with and without chronic kidney disease
and is associated with increased mortality rate. Kidney Int 2011; 80:
181–189.
Sergey V. Brodsky1, Brad H. Rovin2 and
Lee A. Hebert2
1Department of Pathology, Ohio State University, Columbus, Ohio, USA and
2Division of Nephrology, Department of Internal Medicine, Ohio State
University, Columbus, Ohio, USA
Correspondence: Sergey V. Brodsky, Department of Pathology, Ohio State
University, 333 W 10th Street, B078, Graves Hall, Columbus, Ohio 43210, USA.
E-mail: sergey.brodsky@osumc.edu
Kidney International (2012) 82, 113–114; doi:10.1038/ki.2012.94
‘Apple-green birefringence’ of
amyloid stained by Congo red
To the Editor: On the cover of Issue 2 of the January 2012
Kidney International is an excellent illustration of some
properties of amyloid stained by Congo red, taken from the
article by Sethi et al.1 The ﬁgure is said to show apple-green
birefringence under polarized light, although readers may be
puzzled why the other bright colors, yellow and orange, are
not also mentioned.
We studied 160 papers on Congo red–stained amyloid
and found that virtually all reported just green birefringence
or apple-green birefringence, even though only 31% of the
illustrations showed a pure green color.2 There were
discrepancies between the colors reported and illustrated in
66% of the ﬁgures, and these were mostly discrepancies
between reports of green only and green and another color in
the ﬁgures, or even between reports of green and no green at
all in the ﬁgures. The conclusions are that many papers
assume that green must be seen to make a diagnosis of
amyloid, and that other colors are irrelevant and should be
ignored.
We have explained how pure green, or green and other
colors, or even other colors without green, may be seen and
our papers do not assume specialized knowledge of physical
optics.2–4 We show how the idea arose that green, and parti-
cularly green alone, is essential for the diagnosis of amyloid,
and why this idea is not correct. We also suggest that the most
accurate way to describe the properties of Congo red–stained
amyloid is to say that between a polarizer and a crossed
analyzer there are anomalous colors.
1. Sethi S, Theis JD, Shiller SM et al. Medullary amyloidosis associated with
apolipoprotein A-IV deposition. Kidney Int 2012; 81: 201–206.
2. Howie AJ, Owen-Casey MP. Discrepancies between descriptions and
illustrations of colours in Congo red-stained amyloid, and explanation of
discrepant colours. Amyloid 2010; 17: 109–117.
3. Howie AJ, Brewer DB, Howell D et al. Physical basis of colors seen
in Congo red-stained amyloid in polarized light. Lab Invest 2008; 88:
232–242.
4. Howie AJ, Brewer DB. Optical properties of amyloid stained by Congo red:
history and mechanisms. Micron 2009; 40: 285–301.
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The Authors Reply: We thank Dr Howie and Dr Owen-
Casey for their letter1 in response to our article.2 We agree
that green and green alone is not the color that one sees on
polarization of amyloid material. Indeed, as you point out,
there is green and orange-yellow in our illustration, and in
fact, as one polarizes the amyloid material, there is a change
in color from green to orange-yellow and vice versa, as very
nicely described in your studies. However, we use the term
‘apple-green’ per conventional pathology terminology to
reﬂect the anomalous colors, including green, when amyloid
is examined with a crossed analyzer and polarizer. We thank
you for bringing this to our attention.
1. Howie AJ and Owen-Casey MP. Apple-green birefringence of amyloid
stained by Congo red. Kidney Int 2012; 82: 114.
2. Sethi S, Theis JD, Shiller SM et al. Medullary amyloidosis associated with
apolipoprotein A-IV deposition. Kidney Int 2012; 81: 201–206.
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Benefits of frequent nocturnal
home hemodialysis
To the Editor: Only 87 patients could be randomized for the
trial by Rocco et al. (Frequent Hemodialysis Network Trial
Group).1 Contrary to the study on frequent short dialysis, in
which patients with substantial residual renal function were
excluded from randomization, 57.2% of the patients in the
control group had a urine output of 4500ml/day (including
19.1% who had a urine output of 41 l/day). Patients with a
urine output of41 l/day do not require high-dose dialysis. In
the past such patients were not dialyzed unless their urine
output dropped below 1000ml/day, and they achieved clinically
adequate dialysis with long, twice-weekly sessions if the urine
output exceeded 500ml/day.2 Further indication of an
l e t te r to the ed i to r
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inappropriate selection of patients for randomization is the
fact that mortality in the conventional arm was 1/42¼ 2.38%,
which is at least 7 times lower than that in the general
population of hemodialysis (HD) patients in the United States.
Many patients in the control group performed more frequent
dialysis sessions and those in the more frequent group
performed less frequent dialyses. The ultimate conclusion that
was reached was that the frequent nocturnal dialysis study
group had improvement in ‘‘control of hyperphosphatemia
and hypertension but no beneﬁt among other main secondary
outcomes’’. Improvement of left ventricular mass was rejected
as insigniﬁcant on the basis of a P-value of 0.09, which means a
chance difference probability of 1 in 11 instead of 1 in 20. We
wonder whether the Student’s paired t-test, if performed in
the patients in the ‘frequent group’, would show that a
decrease of left ventricular mass from an average of 141 to 132
was in fact statistically signiﬁcant. In all, this study committed
a type II statistical error because of the evidently small
number and inappropriate selection of subjects. On the basis
of this study it absolutely cannot be accepted that frequent
nocturnal HD is not better than conventional thrice-weekly
HD. Interestingly, the front page of Kidney International
egregiously highlights the rather misperceived notion that
frequent nocturnal HD is of no beneﬁt!
1. Rocco MV, Lockridge RS, Beck GJ et al. The effects of frequent nocturnal
home hemodialysis: the Frequent Hemodialysis Network Nocturnal Trial.
Kidney Int 2011; 80: 1080–1091.
2. Twardowski Z. Significance of certain measurable parameters in
the evaluation of haemodialysis adequacy. Acta Med Pol 1974; 15:
245–254.
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The Authors Reply: Drs Misra and Twardowski1 claim that
subjects in the Frequent Hemodialysis Network (FHN)
Nocturnal Trial2 were inappropriately selected. All rando-
mized subjects in the Nocturnal Trial had stage V chronic
kidney disease and o20% of subjects had a urea clearance
43ml/min. Although the mortality rate in both the FHN
Daily and Nocturnal Trials was lower than that seen in the
general hemodialysis population, this observation is common
to randomized clinical trials and is likely due to the exclusion
of subjects with a limited life expectancy who would not be
inﬂuenced by the intervention. Less than 10% of subjects in
the control arm performed dialysis X4 times per week
(Figure 2)2 and 72% of subjects in the more frequent arm had
X4.8 treatments per week (Table 2).2 In addition, the separa-
tion in the weekly dose of dialysis between arms was robust
(total weekly standard Kt/Vurea of 5.03±1.23 vs. 2.91±0.86,
Po0.001). While our ﬁndings for left ventricular mass (LVM)
did not achieve statistical signiﬁcance, the mean change and
95% conﬁdence intervals for LVM were not materially
different from the results of the FHN Daily Trial.3 We
provided several possible explanations for the non-signiﬁcant
effect of more frequent dialysis on LVM in our discussion,2 as
did Davenport in his commentary.4 Finally, the summary
statement on the front cover was not written by the authors
but was provided by the Kidney International staff. We did
not conclude that there is no beneﬁt of nocturnal dialysis
on LVM.
1. Misra M, Twardowski ZJ. Benefits of frequent nocturnal home
hemodialysis. Kidney Int 2012; 82: 114–115.
2. Rocco MV, Lockridge RS, Beck GJ et al. The effects of frequent nocturnal
home hemodialysis: the Frequent Hemodialysis Network Nocturnal Trial.
Kidney Int 2011; 80: 1080–1091.
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Implausible similarities in patient
characteristics between two
randomized controlled studies: a
coincidence is unlikely
To the Editor: We have read the interesting article of the
randomized controlled trial (RCT) by Goraya et al.1 showing
that 30-day dietary acid reduction with an aggressive intake of
fruits and vegetables (FþV) has a renoprotective effect for stage
2 chronic kidney disease (CKD). Despite the small sample
size, it clearly demonstrated the efﬁcacy of FþV by both
clinical and experimental surrogate markers. Its effect is
almost the same with that of sodium bicarbonate, which had
already been shown to attenuate the rate of decline of the
glomerular ﬁltration rate in a 5-year RCT by the same group
of this study.2 Thus, FþV without the increase in sodium
intake may be more favorable than sodium bicarbonate for
early CKD patients.
However, the characteristics of the participants with
stage 2 CKD between these two RCTs are implausibly
similar (Table 1). These similarities are impossible for two
separate RCTs with at least a 5-year interval. Even if these
studies were conducted in parallel without a detailed
l e t te r to the ed i to r
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